125 related articles for article (PubMed ID: 35063353)
1. A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment.
Elshami M; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Chavin KD; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2022 Aug; 24(8):1280-1290. PubMed ID: 35063353
[TBL] [Abstract][Full Text] [Related]
2. Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers.
Elshami M; Ahmed FA; Kakish H; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2023 Feb; 25(2):239-251. PubMed ID: 36411233
[TBL] [Abstract][Full Text] [Related]
3. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma.
Elshami M; Ahmed FA; Kakish H; Hue JJ; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
HPB (Oxford); 2022 Nov; 24(11):1878-1887. PubMed ID: 35961931
[TBL] [Abstract][Full Text] [Related]
4. Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies.
Elshami M; Ahmed FA; Hue JJ; Kakish H; Hoehn RS; Rothermel LD; Bajor D; Mohamed A; Selfridge JE; Ammori JB; Hardacre JM; Winter JM; Ocuin LM
Surgery; 2023 Feb; 173(2):289-298. PubMed ID: 36402613
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
6. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems.
Hue JJ; Katayama ES; Markt SC; Elshami M; Saltzman J; Bajor D; Hosmer A; Mok S; Dumot J; Ammori JB; Rothermel LD; Hardacre JM; Winter JM; Ocuin LM
Surgery; 2022 Jul; 172(1):257-264. PubMed ID: 34839935
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
Yu J; Refsum E; Helsingen LM; Folseraas T; Ploner A; Wieszczy P; Barua I; Jodal HC; Melum E; Løberg M; Blom J; Bretthauer M; Adami HO; Kalager M; Ye W
United European Gastroenterol J; 2022 Mar; 10(2):212-224. PubMed ID: 35107865
[TBL] [Abstract][Full Text] [Related]
8. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data.
Bagante F; Spolverato G; Ruzzenente A; Luchini C; Tsilimigras DI; Campagnaro T; Conci S; Corbo V; Scarpa A; Guglielmi A; Pawlik TM
Eur J Cancer; 2021 May; 148():348-358. PubMed ID: 33774439
[TBL] [Abstract][Full Text] [Related]
9. Promise and pitfalls of immune checkpoint inhibitors in hepato-pancreato-biliary malignancies.
McLoughlin KC; Brown ZJ; Shukla Y; Shukla V
Discov Med; 2018 Sep; 26(142):85-92. PubMed ID: 30399326
[TBL] [Abstract][Full Text] [Related]
10. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.
Wan S; Zhao E; Weissinger D; Krantz BA; Werba G; Freeman D; Khanna LG; Siolas D; Oberstein PE; Chattopadhyay PK; Simeone DM; Welling TH
Front Immunol; 2023; 14():1067352. PubMed ID: 36798126
[TBL] [Abstract][Full Text] [Related]
11. Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer.
Eskander MF; Gil L; Beal EW; Li Y; Hamad A; Oppong B; Obeng-Gyasi S; Tsung A
Ann Surg Oncol; 2022 Feb; 29(2):1271-1277. PubMed ID: 34655352
[TBL] [Abstract][Full Text] [Related]
12. Cholecystitis and risk of pancreatic, liver, and biliary tract cancer in patients undergoing cholecystectomy.
Uldall Torp NM; Kristensen SB; Mortensen FV; Kirkegård J
HPB (Oxford); 2020 Sep; 22(9):1258-1264. PubMed ID: 31843443
[TBL] [Abstract][Full Text] [Related]
13. Clinical Benefit of Preoperative Exercise and Nutritional Therapy for Patients Undergoing Hepato-Pancreato-Biliary Surgeries for Malignancy.
Nakajima H; Yokoyama Y; Inoue T; Nagaya M; Mizuno Y; Kadono I; Nishiwaki K; Nishida Y; Nagino M
Ann Surg Oncol; 2019 Jan; 26(1):264-272. PubMed ID: 30367303
[TBL] [Abstract][Full Text] [Related]
14. Surgical outcomes of pulmonary metastasis from hepatopancreatobiliary carcinomas: a comparison with pulmonary metastasis from colorectal carcinomas.
Kaiho T; Suzuki H; Yamamoto T; Morimoto J; Sakairi Y; Wada H; Nakajima T; Yoshino I
Surg Today; 2019 Sep; 49(9):762-768. PubMed ID: 30859309
[TBL] [Abstract][Full Text] [Related]
15. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.
Riner AN; Girma S; Vudatha V; Mukhopadhyay N; Skoro N; Gal TS; Freudenberger DC; Herremans KM; George TJ; Trevino JG
J Clin Oncol; 2022 Jul; 40(20):2193-2202. PubMed ID: 35316089
[TBL] [Abstract][Full Text] [Related]
16. Geographical and Temporal Variation in the Incidence and Mortality of Hepato-Pancreato-Biliary Primary Malignancies:1990-2017.
Weaver AJ; Stafford R; Hale J; Denning D; Sanabria JR;
J Surg Res; 2020 Jan; 245():89-98. PubMed ID: 31404895
[TBL] [Abstract][Full Text] [Related]
17. Academic status does not affect outcome following complex hepato-pancreato-biliary procedures.
Altieri MS; Yang J; Groves D; Yin D; Cagino K; Talamini M; Pryor A
Surg Endosc; 2018 May; 32(5):2355-2364. PubMed ID: 29101562
[TBL] [Abstract][Full Text] [Related]
18. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.
Rich NE; Hester C; Odewole M; Murphy CC; Parikh ND; Marrero JA; Yopp AC; Singal AG
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):551-559.e1. PubMed ID: 29859983
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment of hepato-pancreato-biliary disease in China: the Tongji experience.
Zhang B; Dong W; Luo H; Zhu X; Chen L; Li C; Zhu P; Zhang W; Xiang S; Zhang W; Huang Z; Chen XP
Sci China Life Sci; 2016 Oct; 59(10):995-1005. PubMed ID: 27585922
[TBL] [Abstract][Full Text] [Related]
20. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer.
Keane MG; Horsfall L; Rait G; Pereira SP
BMJ Open; 2014 Nov; 4(11):e005720. PubMed ID: 25410605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
